<DOC>
	<DOC>NCT01213823</DOC>
	<brief_summary>The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin and/or micafungin.</brief_summary>
	<brief_title>Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis, Invasive</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Acutecare inpatients; Aged 18 years or older; At least one dose of echinocandin therapy during the hospitalization; Primary or secondary ICD9 discharge diagnosis of invasive candidiasis / candidemia. &lt; 18 years of age; No recorded echinocandin therapy during hospitalization; Acetaminophen hepatotoxicity; Preexisting autoimmune hepatitis; Autoimmune/metabolic liver disease; Primary biliary cirrhosis; Primary sclerosing cholangitis and orthotopic liver transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>invasive candidiasis</keyword>
	<keyword>candidemia</keyword>
	<keyword>severe hepatic injury</keyword>
	<keyword>echinocandins</keyword>
	<keyword>anidulafungin</keyword>
	<keyword>caspofungin</keyword>
	<keyword>micafungin</keyword>
</DOC>